Nov-08(1)

The EC Pharmaceutical Report

Kent Bernard, Nov 12, 2008

The 2008 EC Sector Inquiry Regarding Pharmaceuticals: What Does It Mean from a Research-Based Company Perspective?

A sector inquiry is never pleasant for the sector involved. It is much like going to the dentist for a checkup. The best possible result is that after all is said and done, nothing was wrong and life can go on. Well, this checkup began with a bang. On January 16, 2008, the European Commission launched a sector inquiry by staging a series of dawn raids on a number of pharmaceutical companies, with no suggestion of specific wrongdoing. The expressed reasons for the inquiry are puzzling.

Sean-Paul Brankin, Nov 12, 2008

The Pharmaceutical Inquiry: Anything to Report?

One reaction to the pharmaceuticals sector inquiry, particularly from the originator side of the industry, has been to question the need for the investigation. What is certain is that the Commission has set itself a challenging task. It has chosen to investigate a number of competition law issues that are likely to pose substantial legal and evidential difficulties. However, the sector, and originators in particular, cannot afford to be complacent. Information already in the public domain suggests that the industry probably should not expect to be given a clean bill of health.

Thomas Cueni, Nov 12, 2008

The EC Pharmaceutical Inquiry: Behind the Headlines, What is the Real Story on Innovation and Generic Competition in Pharmaceuticals?

ACCESS TO THIS ARTICLE IS RESTRICTED TO SUBSCRIBERS

Please sign in or join us
to access premium content!